There are 2137 resources available
1264P - Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer (SQ NSCLC)
Presenter: Jie Wang
Session: E-Poster Display
Resources:
Abstract
1265P - IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations
Presenter: Howard West
Session: E-Poster Display
Resources:
Abstract
1266P - Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected first-line metastatic non-small cell lung carcinoma
Presenter: Margarita Majem
Session: E-Poster Display
Resources:
Abstract
1267P - Efficacy of camrelizumab (SHR-1210) plus apatinib as second-line treatment for advanced squamous NSCLC
Presenter: Guanghui Gao
Session: E-Poster Display
Resources:
Abstract
1268P - JASPER: Efficacy and safety of first-line (1L) niraparib plus a programmed death receptor 1 inhibitor (PD-1i) in patients with advanced non-small cell lung cancer (NSCLC)
Presenter: Suresh Ramalingam
Session: E-Poster Display
Resources:
Abstract
1269P - EMPOWER-lung 4: Phase II, randomized, open-label high dose or standard dose cemiplimab alone/plus ipilimumab in the second-line treatment of advanced non-small cell lung cancer (NSCLC)
Presenter: Byoung Yong Shim
Session: E-Poster Display
Resources:
Abstract
1270P - IMscin001: Phase Ib dose-finding study of subcutaneous atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Presenter: Mauricio Burotto
Session: E-Poster Display
Resources:
Abstract
1271P - 4-year survival in randomised phase II (POPLAR) and phase III (OAK) studies of atezolizumab (atezo) vs docetaxel (doc) in pre-treated NSCLC
Presenter: Julien Mazieres
Session: E-Poster Display
Resources:
Abstract
1272P - Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC)
Presenter: Luis Paz-Ares
Session: E-Poster Display
Resources:
Abstract
1273P - Durvalumab (D) compared to maintenance chemotherapy (SoC) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): Results from the randomized SAFIR02 LUNG-IMMUNO trial
Presenter: Fabrice Barlesi
Session: E-Poster Display
Resources:
Abstract